Global Access to Multiple Myeloma Therapies
JCO Global Oncology · 2025-06 · (11)
DOI: 10.1200/go-24-00441 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2025-06. Verfasst von Rawan Atallah und 20 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS. Hauptthemen laut MEDLINE: Multiple Myeloma, Health Services Accessibility. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 60 Literaturangaben.
Abstract (Originalsprache)
PURPOSE Initial reports indicate that access to contemporary therapies currently used in North America for the treatment of multiple myeloma (MM) varies internationally. No studies have quantitatively reported the extent of disparities in the access to MM therapies worldwide, with a goal to investigate access to MM therapies and barriers globally. METHODS From June 18 to July 15, 2023, an electronic survey was distributed to 176 oncologists treating MM outside the United States. MM drugs were categorized by accessibility, with the cutoff for adequate access set at 60% of respondents affirming easy/moderate access. RESULTS Ninety-five (54%) respondents from 33 countries completed the survey. Fifty-one percent of the respondents were from university-based academic programs, and 17% of the responders treated only plasma cell disorders. Most respondents had adequate access to noncellular MM therapies, except for isatuximab, ixazomib, selinexor, and elotuzumab. Among the cellular therapies, 17% had access to Chimeric Antigen Receptor T-cell therapy, whereas 23% had access to approved T-cell engagers (TCEs). Financial stress on patients and health care systems has emerged as a primary barrier to global inaccessibility of treatment drugs. CONCLUSION Global access to novel MM therapies remains challenging, and we have identified barriers and suggested strategies to bridge this gap.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS.
- US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS.
- Jordan University of Science & Technology, Irbid, Jordan.
- Department of Internal Medicine Trinity Health Oakland/Wayne State University, Detroit, MI.
- Department of Biostatistics & Data Science, University of Kansas Medical Center, Kansas City, KS.
- International Baccalaureate, Erindale Secondary School, Mississauga, ON, Canada.
ORCID-Profile: Rawan Atallah, Yara Shatnawi, Emerson Logan, Muhammad Umair Mushtaq, Aytaj Mammadzadeh, Thiago Xavier Carneiro, Rakesh Popat, Joseph P McGuirk, Shebli Atrash, Zahra Mahmoudjafari, Nada Hammad, Faiz Anwer, Nausheen Ahmed, Al-Ola Abdallah
Zitieren
APA
Atallah, R., Shatnawi, Y., Ayoobkhan, M. F. S., Saif, M. S. I., Naeem, M., Logan, E., Mushtaq, M. U., Rana, S., Mammadzadeh, A., Hashmi, S. K., Mohamed, B., Desai, N., Carneiro, T. X., Popat, R., McGuirk, J. P., Atrash, S., Mahmoudjafari, Z., Hammad, N., Anwer, F., …, & Abdallah, A. O. (2025). Global Access to Multiple Myeloma Therapies. JCO Global Oncology. https://doi.org/10.1200/go-24-00441
Vancouver
Atallah R, Shatnawi Y, Ayoobkhan MFS, Saif MSI, Naeem M, Logan E, et al. Global Access to Multiple Myeloma Therapies. JCO Global Oncology. 2025. doi:10.1200/go-24-00441
BibTeX
@article{Atallah2025,
author = {Atallah, Rawan and Shatnawi, Yara and Ayoobkhan, Md Fathima Shehnaz and Saif, Md Saiful Islam and Naeem, Menahil and Logan, Emerson and Mushtaq, Muhammad Umair and Rana, Shabeeha and Mammadzadeh, Aytaj and Hashmi, Shahrukh K and Mohamed, Benlazar and Desai, Nihar and Carneiro, Thiago Xavier and Popat, Rakesh and McGuirk, Joseph P and Atrash, Shebli and Mahmoudjafari, Zahra and Hammad, Nada and Anwer, Faiz and Ahmed, Nausheen and Abdallah, Al-Ola},
title = {Global Access to Multiple Myeloma Therapies},
journal = {JCO Global Oncology},
year = {2025},
number = {11},
doi = {10.1200/go-24-00441}
}
EUVIMED